Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Clasificación en acciones #16898
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Precio por acción
$2.46
Capitalización bursátil
$268.65M
Cambio (1 día)
-1.73%
Cambio (1 año)
-57.06%
País
CN
Comercio VISEN Pharmaceuticals (2561)

Categoría

Historial de desdoblamientos de acciones de VISEN Pharmaceuticals (2561)
La acción VISEN Pharmaceuticals (símbolo: 2561) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Sep 02, 2026.
Una acción 2561 comprada antes de Sep 02, 2026 equivaldría hoy a 0 acciones 2561.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
0 -
DE
0 -
DE
0 -
JP
5 x119
IN
0 -
CH